DSP-6745 is a serotonergic agent which was under development for the treatment of psychotic disorders but was never marketed. It is taken orally.
The drug acts as a serotonin reuptake inhibitor (SRI) and as an antagonist of the serotonin 5-HT2A, 5-HT2C, and 5-HT7 receptors. Its affinities (Ki) were 0.653nM for the serotonin transporter (SERT), 0.331nM for the serotonin 5-HT2A receptor, 1.34nM for the serotonin 5-HT2C receptor, and 31.7nM for the serotonin 5-HT7 receptor. Conversely, its or Kb values were 0.753nM at the SERT, 0.566nM at the serotonin 5-HT2A receptor, 1.37nM at the serotonin 5-HT2C receptor, and 2.12nM at the serotonin 5-HT7 receptor. It also shows lower affinity for a number of other receptors, such as the serotonin 5-HT2B receptor (Ki = 7.58nM). DSP-6745 produces antidepressant-like, anxiolytic-like, antipsychotic-like, and pro-cognitive effects in animals.
The chemical synthesis of DSP-6745 has been described.
DSP-6745 was first described in the scientific literature by 2024. It was under development by Sumitomo Dainippon Pharma or Sumitomo Pharma. The drug reached phase 1 clinical trials for psychotic disorders prior to the discontinuation of its development in November 2022.
See also List of investigational antipsychotics Serotonin antagonist and reuptake inhibitor (SARI) Serotonin modulator and stimulator (SMS)
References